Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX

F. Albers (Research Triangle Park, United States of America), S. Khurana (Rochester, United States of America), E. Bradford (Research Triangle Park, United States of America), M. Gilson (Stockley Park, Uxbridge, United Kingdom), R. Price (Stevenage, United Kingdom), G. Brusselle (Ghent, Belgium), E. Bel (Amsterdam, Netherlands), J. Fitzgerald (Vancouver, Canada), M. Masoli (Plymouth, United Kingdom), S. Korn (Mainz, Germany), M. Humbert (Le Kremlin-Bicêtre, France)

Source: International Congress 2018 – Notable Studies in Asthma
Session: Notable Studies in Asthma
Session type: Oral Presentation
Number: 3566
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Albers (Research Triangle Park, United States of America), S. Khurana (Rochester, United States of America), E. Bradford (Research Triangle Park, United States of America), M. Gilson (Stockley Park, Uxbridge, United Kingdom), R. Price (Stevenage, United Kingdom), G. Brusselle (Ghent, Belgium), E. Bel (Amsterdam, Netherlands), J. Fitzgerald (Vancouver, Canada), M. Masoli (Plymouth, United Kingdom), S. Korn (Mainz, Germany), M. Humbert (Le Kremlin-Bicêtre, France). Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX. 3566

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: